We further show that BUB1B variants lead to decreased BubR1 expression and/or stability, which promotes increased premature chromatid separation and, consequently, triggers CIN, driving resistance to Taxol-based therapies. The gene discussed is BUB1B; the disease is cervical squamous intraepithelial neoplasia.